SGD Pharma takes its global and local responsibilities seriously and works consistently to be compliant with all environmental, social and ethical requirements. The publication of the SGD Pharma’s 2022 sustainability report reinforces the company-wide commitment to a green and sustainable present and future.
Download the full report here.
Key highlights of SGD Pharma CSR report 2022
• 100 percent of all SGD Pharma owned glass manufacturing plants are ISO 45001 certified
• 100 percent of SGD Pharma sites are certified with ISO 14001
• 100 percent of critical suppliers have CSR clauses in their contracts
• 99.5 percent of internal cullet is reused in production process
• >20 percent reduction in water consumption vs 2020
• 86 percent EHS Maturity Matrix
Zhanjiang China CSR spotlight – planting mangroves
As well as being SA 8000 certified, the SGD Pharma Chinese plant in Zhanjiang supports the local community by its local footprint, relationships with local government and institutions, local hiring policies and by helping to protect biodiversity in Zhanjiang. The city is home to one of the world’s most successful examples of wetland ecological restoration and SGD Pharma has committed to supporting the community’s efforts to tackle deforestation by planting mangrove trees.
By the end of 2022, SGD Pharma employees planted a total of 1,000 mangroves trees on the beach at Zhanjiang Nanshan Island, China, in association with Zhanjiang Nature and Resource Bureau and Guangdong Ocean University.
During a visit to the SGD Pharma Zhanjiang plant in April 2023, Mayor Zeng Jinze joined SGD Pharma’s CEO Olivier Rousseau to plant new mangrove roots and stressed the importance of mangrove preservation for Zhanjiang and the many benefits it brings to society in terms of biodiversity, carbon sync and protection of the coast. SGD Pharma is proud to contribute to biodiversity and will continue to support projects in China and other plants during 2023.
Rating for sustainability
SGD Pharma has been awarded Gold EcoVadis rating for the year 2022, highlighting the actions the company has implemented through its global CSR strategy to improve the way the business operates and how it treats both its employees and the environment.
SGD Pharma is proud to have achieved its highest ever score of 75 out of 100, which places the company in the top 2 percent of global companies in the ‘Manufacture of glass and glass products’ category.
Next steps
The renewed company-wide focus on CSR means stretch targets have been set ahead, these include:
• Achieve Excellence rating in Quality Maturity Matrix by 2025
• Halve Scope 1 and Scope 2 emissions by 2030
• 35 percent reduction in carbon footprint by 2030
• 65 percent reduction in carbon footprint by 2040 (compared with 2020 baseline)
• Goal: Zero accidents